

ADDITIONAL U.S. PATENTS FOR LEAD CANCER DRUG CANDIDATE STRENGTHEN CRITICAL OUTCOME'S INVESTMENT PROPOSITION

**COTI-2 continues to increase in value with four U.S. patents
granted and several more pending**

London, Ontario (April 26, 2013): Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSXV: COT) is pleased to announce that the United States ("U.S.") Patent and Trademark Office has recently granted two patents for the Company's lead oncology asset, COTI-2. These build on two previously granted patents in providing further protection and added value to the compound.

"These additional patents provide further support for developing COTI-2 as an exciting new cancer therapy," said Dr. Wayne Danter, President and CEO of COTI. "The continued strengthening of our patent position is consistent with our extensive pre-clinical evaluation of the drug. We believe it is only a matter of time before the world recognizes the importance of COTI-2 to cancer treatment and a partner comes forward to take this drug to the clinic."

Newly issued patents

U.S. Patent 8,367,675 covers methods of treatment of various cancers using the family of compounds to which COTI-2 belongs. This patent provides additional support for the clinical use of the broad family of compounds.

U.S. Patent 8,420,643 covers a subset of the COTI-2 family in order to provide additional support for the compounds found most useful in pre-clinical testing.

About Critical Outcome Technologies Inc.

COTI is a leading-edge technology company specializing in accelerating the discovery and development of small molecules – dramatically reducing the time and cost to bring new drugs to market. COTI'S proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit www.criticaloutcome.com or contact:

Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
Tel: 519-858-5157
Email: wdanter@criticaloutcome.com

Heisler Communications
Trevor Heisler
Investor Relations
Tel: 416-500-8061
Email: trevor@heislercommunications.com

Follow @CriticalOutcome on Twitter at <http://twitter.com/CriticalOutcome>

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.